Apelin and Testosterone Levels in Men with Metabolic Syndrome


Apelin is a new adipokine associated with obesity. Data about the relationship of apelin to the metabolic syndrome (MS) are still scarce. Late-onset hypogonadism (LOH) is common in men with MS, but we did not find data about the levels of apelin in men with LOH. The aim of this study is to determine the levels of apelin in men with MS with or without LOH. Patients and Methods: 99 men are included in the study. Of them 65 have MS (IDF 2005) and they are divided according to their morning total testosterone (TT) level (cutoff 10.4 nmol/l) into two groups: MS-low T (N = 21) and MS-normal T (N = 44). The control group consists of 34 men without MS and with normal T. Apelin is determined in serum using enzyme linked immunosorbent assay. Some of the men were additionally assigned to testosterone treatment and monitored. Results: MS men are at mean age (±SD) = 50.4 ± 9.6 years and TT = 13.6 ± 5.4 nmol/l. The control group is at age = 51.5 ± 6.4 years (NS) and TT = 17.9 ± 5.6 nmol/l (p < 0.001). The levels of apelin are higher in the MS group—1.61 ± 0.53 ng/ml compared to the control one—1.38 ± 0.57 ng/ml (p < 0.05). There is no difference between MS-lowT—1.53 ± 0.52 ng/ml and MS-normal T —1.65 ± 0.53 ng/ml sub-groups. The MS-normal T differs from the control group (p < 0.05). Significant correlation of testosterone with apelin levels is not found. Although apelin correlates with other laboratory parameters: LDL-levels in the MS-patients (Pearson’s = 0.311, p < 0.05); HbA1c in men with T2DM (Pearson’s = 0.285, p < 0.05); serum creatinine levels (Pearson’s = 0.257, p < 0.001). The patients that are assigned to testosterone substitution show a trend for lowering apelin levels. Conclusions: In this study, higher apelin levels are found in the presence of MS compared to healthy men, but do not differ between men having MS with low or normal T.

Share and Cite:

P. Angelova, Z. Kamenov and A. Tsakova, "Apelin and Testosterone Levels in Men with Metabolic Syndrome," Open Journal of Endocrine and Metabolic Diseases, Vol. 4 No. 2, 2014, pp. 35-43. doi: 10.4236/ojemd.2014.42004.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. Boucher, B. Masri, D. Daviaud, S. Gesta, C. Guigne, A. Mazzucotelli, et al., “Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity,” Endocrinology, Vol. 146, No. 4, 2005, pp. 1764-1771.
[2] K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Kakegawa, M. X. Zou, et al., “Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ Receptor,” Biochemical and Biophysical Research Communications, Vol. 251, No. 2, 1998, pp. 471-476.
[3] B. O’Dowd, M. Heiber, A. Chan, H. Heng, L. Tsui, J. Kennedy, et al., “A Human Gene That Shows Identity with the Gene Encoding the Angiotensin Receptor Is Located on Chromosome 11,” Gene, Vol. 136, No. 1-2, 1993, pp. 355-360.
[4] A. D. Medhurst, C. A. Jennings, M. J. Robbins, R. P. Davis, C. Ellis, K. Y. Winborn, et al., “Pharmacological and Immunohistochemical Characterization of the APJ Receptor and Its Endogenous Ligand Apelin,” Journal of Neurochemistry, Vol. 84, No. 5, 2003, pp. 1162-1172.
[5] A. M. O’Carroll, T. L. Selby, M. Palkovits and S. J. Lolait, “Distribution of mRNA Encoding B78/APJ, the Rat Homologue of the Human APJ Receptor, and Its Endogenous Ligand Apelin in Brain and Peripheral Tissues,” Biochimica et Biophysica Acta, Vol. 1492, No. 1, 2000, pp. 72-80.
[6] I. Falcao-Pires and A. F. Leite-Moreira, “Apelin: A Novel Neurohumoral Modulator of the Cardiovascular System: Pathophysiologic Importance and Potential Use as a Therapeutic Target,” Revista Portuguesa de Cardiologia, Vol. 24, No. 10, 2005, pp. 1263-1276.
[7] M. J. Kleinz and A. P. Davenport, “Emerging Roles of Apelin in Biology and Medicine,” Pharmacology & Therapeutics, Vol. 107, No. 2, 2005, pp. 198-211.
[8] B. Masri, B. Knibiehler and Y. Audigier, “Apelin Signalling: A Promising Pathway from Cloning to Pharmacology,” Cell Signaling, Vol. 17, No. 4, 2005, pp. 415-426.
[9] R. Ladeiras-Lopes, J. Ferreira-Martins and A. F. LeiteMoreira, “The Apelinergic System: The Role Played in Human Physiology and Pathology and Potential Therapeutic Applications,” Arquivos Brasileiros de Cardiologia, Vol. 90, No. 5, 2008, pp. 343-349.
[10] D. K. Lee, R. Cheng, T. Nguyen, T. Fan, A. P. Kariyawasam, Y. Liu, et al., “Characterization of Apelin, the Ligand for the APJ Receptor,” Journal of Neurochemistry, Vol. 74, No. 1, 2000, pp. 34-41.
[11] K. Tatemoto, K. Takayama, M. X. Zou, I. Kumaki, W. Zhang, K. Kumano, et al., “The Novel Peptide Apelin Lowers Blood Pressure via a Nitric Oxide-Dependent Mechanism,” Regulatory Peptides, Vol. 99, No. 2-3, 2001, pp. 87-92. http://dx.doi.org/10.1016/S0167-0115(01)00236-1
[12] S. D. Katugampola, J J. Maguire, S. R. Matthewson and A. P. Davenport, “[(125)I]-(Pyr(1))Apelin-13 Is a Novel Radioligand for Localizing the APJ Orphan Receptor in Human and Rat Tissues with Evidence for a Vasoconstrictor Role in Man,” British Journal of Pharmacology, Vol. 132, No. 6, 2001, pp. 1255-1260.
[13] A. Reaux, N. De Mota, I. Skultetyova, Z. Lenkei, S. El Messari, K. Gallatz, et al., “Physiological Role of a Novel Neuropeptide, Apelin, and Its Receptor in the Rat Brain,” Journal of Neurochemistry, Vol. 77, No. 4, 2001, pp. 1085-1096.
[14] M. Sorhede Winzell, C. Magnusson and B. Ahren, “The APJ Receptor Is Expressed in Pancreatic Islets and Its Ligand, Apelin, Inhibits Insulin Secretion in Mice,” Regulatory Peptides, Vol. 131, No. 1-3, 2005, pp. 12-17.
[15] M. V. Heinonen, A. K. Purhonen, P. Miettinen, M. Paakkonen, E. Pirinen, E. Alhava, et al., “Apelin, Orexin-A and Leptin Plasma Levels in Morbid Obesity and Effect of Gastric Banding,” Regulatory Peptides, Vol. 130, No. 1-2, 2005, pp. 7-13.
[16] L. Li, G. Yang, Q. Li, Y. Tang, M. Yang, H. Yang, et al., “Changes and Relations of Circulating Visfatin, Apelin, and Resistin Levels in Normal, Impaired Glucose Tolerance, and Type 2 Diabetic Subjects,” Experimental and Clinical Endocrinology & Diabetes, Vol. 114, No. 10, 2006, pp. 544-548.
[17] K. Higuchi, T. Masaki, K. Gotoh, S. Chiba, I. Katsuragi, K. Tanaka, et al., “Apelin, an APJ Receptor Ligand, Regulates Body Adiposity and Favors the Messenger Ribonucleic Acid Expression of Uncoupling Proteins in Mice,” Endocrinology, Vol. 148, No. 6, 2007, pp. 2690-2697.
[18] N. E. Allen, P. N. Appleby, G. K. Davey and T. J. Key, “Lifestyle and Nutritional Determinants of Bioavailable Androgens and Related Hormones in British Men,” Cancer Causes and Control, Vol. 13, No. 4, 2002, pp. 353-363.
[19] R. R. Kalyani and A. S. Dobs, “Androgen Deficiency, Diabetes, and the Metabolic Syndrome in Men,” Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 14, 2007, pp. 226-234.
[20] V. Kupelian, S. T. Page, A. B. Araujo, T. G. Travison, W. J. Bremner and J. B. McKinlay, “Low Sex HormoneBinding Globulin, Total Testosterone, and Symptomatic Androgen Deficiency Are Associated with Development of the Metabolic Syndrome in Nonobese Men,” Journal of Clinical Endocrinology & Metabolism, Vol. 91, No. 3, 2006, pp. 843-850.
[21] M. Muller, D. E. Grobbee, I. den Tonkelaar, S. W. Lamberts and Y. T. van der Schouw, “Endogenous Sex Hormones and Metabolic Syndrome in Aging Men,” Journal of Clinical Endocrinology & Metabolism, Vol. 90, No. 5, 2005, pp. 2618-2623.
[22] S. A. Kaplan, A. G. Meehan and A. Shah, “The Age Related Decrease in Testosterone Is Significantly Exacerbated in Obese Men with the Metabolic Syndrome. What Are the Implications for the Relatively High Incidence of Erectile Dysfunction Observed in These Men?” Journal of Urology, Vol. 176, No. 4, 2006, pp. 1524-1528.
[23] A. Т. Guay, “The Emerging Link between Hypogonadism and Metabolic Syndrome,” Journal of Andrology, Vol. 30, No. 4, 2009, pp. 370-376.
[24] A. Rodriguez, D. C. Muller, E. J. Metter, M. Maggio, S. M. Harman, M. R. Blackman and R. Andres, “Aging, Androgens, and the Metabolic Syndrome in a Longitudinal Study of Aging,” Journal of Clinical Endocrinology & Metabolism, Vol. 92, No. 9, 2007, pp. 3568-3572.
[25] D. E. Laaksonen, L. Niskanen, K. Punnonen, K. Nyyssonen, T. P. Tuomainen, V. P. Valkonen and J. T. Salonen, “The Metabolic Syndrome and Smoking in Relation to Hypogonadism in Middle-Aged Men: A Prospective Cohort Study,” Journal of Clinical Endocrinology & Metabolism, Vol. 90, No. 2, 2005, pp. 712-719.
[26] ‘The IDF Consensus Worldwide Definition of the Metabolic Syndrome,” 2005.
[27] T. Mulligan, M. F. Frick, Q. C. Zuraw, A. Stemhagen and C. McWhirter, “Prevalence of Hypogonadism in Males Aged at Least 45 Years: The HIM Study,” International Journal of Clinical Pharmacy, Vol. 60, No. 7, 2006, pp. 762-769.
[28] J. E. Morley, E. Charlton, P. Patrick, et al., “Validation of a Screening Questionnaire for Androgen Deficiency in Aging Males,” Metabolism, Vol. 49, No. 9, 2000, pp. 1239-1242.
[29] L. A. J. Heinemann, T. Zimmermann, A. Vermeulen and C. Thiel, “A New ‘Aging Male’s Symptoms’ (AMS) Rating Scale,” Aging Male, Vol. 2, No. 2, 1999, pp. 105-114.
[30] S. Yu, Y. Zhang, M. Li, et al., “Chemerin and Apelin Are Positively Correlated with Inflammation in Obese Type 2 Diabetic Patients,” Chinese Medical Journal, Vol. 125, No. 19, 2012, pp. 3440-3444.
[31] F. Soriguer, L. Garrido-Sanchez, S. Garcia-Serrano, et al., “Apelin Levels Are Increased in Morbidly Obese Subjects with Type 2 Diabetes Mellitus,” Obesity Surgery, Vol. 19, No. 11, 2009, pp. 1574-1580.
[32] T. M. Wallace and D. R. Matthews, “The Assessment of Insulin Resistance in Man,” Diabetic Medicine, Vol. 19, No. 7, 2002, pp. 527-534.
[33] T. Reinehr, J. Woelfle and C. L. Roth, “Lack of Association between Apelin, Insulin Resistance, Cardiovascular Risk Factors, and Obesity in Children: A Longitudinal Analysis,” Metabolism—Clinical and Experimental, Vol. 60, No. 9, 2011, pp. 1349-1354.
[34] J. Beltowski and A. Kedra, “Asymmetric Dimethylarginine (ADMA) as a Target for Pharmacotherapy,” Pharmacological Research, Vol. 58, 2006, pp. 159-178.
[35] C. Dray, C. Knauf, D. Daviaud, A. Waget, J. Boucher, M. Buléon, et al., “Apelin Stimulates Glucose Utilization in Normal and Obese Insulin-Resistant Mice,” Cell Metabolism, Vol. 8, No. 5, 2008, pp. 437-445.
[36] I. Castan-Laurell, M. Vítkova, D. Daviaud, C. Dray, M. Kováciková, Z. Kovacova, J. Hejnova, V. Stich and P. Valet, “Effect of Hypocaloric Diet-Induced Weight Loss in Obese Women on Plasma Apelin and Adipose Tissue Expression of Apelin and APJ,” European Journal of Endocrinology, Vol. 158, 2008, pp. 905-910.
[37] M. V. Heinonen, A. K. Purhonen, P. Miettinen, M. Pääkkönen, E. Pirinen, E. Alhava, K. Akerman and K. H. Herzig, “Apelin, Orexin-A and Leptin Serum Levels in Morbid Obesity and Effect of Gastric Banding,” Regulatory Peptides, Vol. 130, No. 1-2, 2005, pp. 7-13.
[38] I. Castan-Laurell, J. Boucher, C. Dray, D. Daviaud, C. Guigné and P. Valet, “Apelin, a Novel Adipokine Over-Produced in Obesity: Friend or Foe?” Molecular and Cellular Endocrinology, Vol. 245, No. 1-2, 2005, pp. 7-9.
[39] L. Li, G. Yang, Q. Li, Y. Tang, M. Yang, H. Yang and K. Li, “Changes and Relations of Circulating Visfatin, Apelin, and Resistin Levels in Normal, Impaired Glucose Tolerance, and Type 2 Diabetic Subjects,” Experimental and Clinical Endocrinology & Diabetes, Vol. 114, No. 10, 2006, pp. 544-548. http://dx.doi.org/10.1055/s-2006-948309
[40] M. V. Heinonen, D. E. Laaksonen, T. Karhu, L. Karhunen, T. Laitinen, S. Kainulainen, A. Rissanen, L. Niskanen and K. H. Herzig, “Effect of Dietinduced Weight Loss on Plasma Apelin and Cytokine Levels in Individuals with the Metabolic Syndrome,” Nutrition, Metabolism & Cardiovascular Diseases, Vol. 19, No. 9, 2009, pp. 626-633.
[41] M. Sörhede Winzell, C. Magnusson and B. Ahrén, “The APJ Receptor Is Expressed in Pancreatic Islets and Its Ligand, Apelin, Inhibits Insulin Secretion in Mice,” Regulatory Peptides, Vol. 131, No. 1-3, 2005, pp. 12-17.
[42] N. P. Kadoglou, I. S. Vrabas, A. Kapelouzou, S. Lampropoulos, N. Sailer, A. Kostakis, C. D. Liapis and N. Angelopoulou, “The Impact of Aerobic Exercise Training on Novel Adipokines, Apelin and Ghrelin, in Patients with Type 2 Diabetes,” Medical Science Monitor, Vol. 18, No. 5, 2012, pp. CR290-CR295.
[43] C. Dray, C. Debard, J. Jager, E. Disse, D. Daviaud, P. Martin, C. Attané, E. Wanecq, C. Guigné, F. Bost, J. F. Tanti, M. Laville, H. Vidal, P. Valet and I. Castan-Laurell, “Apelin and APJ Regulation in Adipose Tissue and Skeletal Muscle of Type 2 Diabetic Mice and Humans,” American Journal of Physiology. Endocrinology and Metabolism, Vol. 298, No. 6, 2010, pp. E1161-E1169.
[44] N. P. Kadoglou, F. Iliadis, N. Angelopoulou, N. Sailer, G. Fotiadis, K. Voliotis, I. Vitta, C. D. Liapis and M. Alevizos, “Cardiorespiratory Capacity Is Associated with Favourable Cardiovascular Risk Profile in Patients with Type 2 Diabetes,” Journal of Diabetes and Its Complications, Vol. 23, No. 3, 2009, pp. 160-166.
[45] I. Tasci, G. Erdem, G. Ozgur, S. Tapan, T. Dogru, H. Genc, C. Acikel, T. Ozgurtas and A. Sonmez, “LDL-Cholesterol Lowering Increases Plasma Apelin in Isolated Hypercholesterolemia,” Atherosclerosis, Vol. 204, No. 1, 2009, pp. 222-228.
[46] M. Brownlee, “The Pathobiology of Diabetes Complications. A Unifying Mechanism,” Diabetes, Vol. 54, No. 6, 2005, pp. 1615-1625.
[47] A. Ceriello, “New Insights on Oxidative Stress and Diabetic Complications May Lead to a ‘Causal’ Antioxidant Therapy,” Diabetes Care, Vol. 26, No. 5, 2003, pp. 1589-1596.
[48] F. Palm, D. G. Buerk, P. O. Carlsson, P. Hansell and P. Liss, “Reduced Nitric Oxide Concentration in the Renal Cortex of Streptozotocin-Induced Diabetic Rats: Effects on Renal Oxygenate and Microcirculation,” Diabetes, Vol. 54, No. 11, 2005, pp. 3282-3287.
[49] C. G. Schnackenberg, “Physiological and Pathophysiological Roles of Oxygen Radicals in the Renal Microvasculature,” American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, Vol. 282, No. 2, 2002, pp. R335-R342.
[50] O. Grisk, “Apelin and Vascular Dysfunction in Type 2 Diabetes,” Cardiovascular Research, Vol. 74, No. 3, 2007, pp. 339-340.
[51] A. Yonem, C. Duran, M. Unal, O. M. Ipcioglu and O. Ozcan, “Plasma Apelin and Asymmetric Dimethylarginine Levels in Type 2 Diabetic Patients with Diabetic Retinopathy,” Diabetes Research and Clinical Practice, Vol. 84, No. 3, 2009, pp. 219-223.
[52] J. C. Zhong, Y. Huang, L. M. Yung, C. W. Lau, F. P. Leung, W. T. Wong, S. G. Lin and X. Y. Yu, “The Novel Peptide Apelin Regulates Intrarenal Artery Tone in Diabetic Mice,” Regulatory Peptides, Vol. 144, No. 1-3, 2007, pp. 109-114.
[53] S. Tapan, E. Tascilar, A. Abaci, A. Sonmez, S. Kilic, M. K. Erbil and O. Ozcan, “Decreased Plasma Apelin Levels in Pubertal Obese Children,” Journal of Pediatric Endocrinology & Metabolism, Vol. 23, No. 10, 2010, pp. 1039-1046. http://dx.doi.org/10.1515/jpem.2010.165

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.